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Abstract
The purpose of this systematic review and meta-analysis of randomized controlled trials (RCTs) is to determine the effectiveness
of probiotic supplementation on clinical symptoms, weight loss, glycemic control, lipid and hormonal profiles, and biomarkers of
inflammation and oxidative stress in women with polycystic ovary syndrome (PCOS). Eligible studies were systematically
searched from Cochrane Library, Embase, Medline, and Web of Science databases until January 2019. Cochran (Q) and I-
square statistics were used to measure heterogeneity among included studies. Data were pooled by using random-effect model
and expressed as standardized mean difference (SMD) with 95% confidence interval (CI). Eleven articles were included in this
meta-analysis. Probiotic supplementation significantly decreased weight (SMD − 0.30; 95% CI, − 0.53, − 0.07; P = 0.01), body
mass index (BMI) (SMD − 0.29; 95% CI, − 0.54, − 0.03; P = 0.02), fasting plasma glucose (FPG) (SMD − 0.26; 95% CI, − 0.45,
− 0.07; P < 0.001), insulin (SMD − 0.52; 95%CI, − 0.81, − 0.24; P < 0.001), homeostatic model assessment for insulin resistance
(HOMA-IR) (SMD − 0.53; 95% CI, − 0.79, − 0.26; P < 0.001), triglycerides (SMD − 0.69; 95% CI, − 0.99, − 0.39; P < 0.001),
VLDL-cholesterol (SMD − 0.69; 95% CI, − 0.99, − 0.39; P < 0.001), C-reactive protein (CRP) (SMD − 1.26; 95% CI, − 2.14, −
0.37; P < 0.001), malondialdehyde (MDA) (SMD − 0.90; 95%CI, − 1.16, − 0.63; P < 0.001), hirsutism (SMD − 0.58; 95%CI, −
1.01, − 0.16; P < 0.001), and total testosterone levels (SMD − 0.58; 95% CI, − 0.82, − 0.34; P < 0.001), and also increased the
quantitative insulin sensitivity check index (QUICKI) (SMD 0.41; 95% CI, 0.11, 0.70; P < 0.01), nitric oxide (NO) (SMD 0.33;
95% CI 0.08, 0.59; P = 0.01), total antioxidant capacity (TAC) (SMD 0.64; 95% CI, 0.38, 0.90; P < 0.001), glutathione (GSH)
(SMD 0.26; 95% CI, 0.01, 0.52; P = 0.04), and sex hormone binding globulin (SHBG) levels (SMD 0.46; 95% CI, 0.08, 0.85;
P = 0.01). Probiotic supplementation may result in an improvement in weight, BMI, FPG, insulin, HOMA-IR, triglycerides,
VLDL-cholesterol, CRP, MDA, hirsutism, total testosterone, QUICKI, NO, TAC, GSH, and SHBG but did not affect dehydro-
epiandrosterone sulfate levels, and total, LDL, and HDL cholesterol levels in patients with PCOS.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder affecting 6–10% of women of repro-
ductive age. PCOS can be characterized by a list of
dysmetabolic features including glucose intolerance, insu-
lin resistance, lipid abnormalities, and increased low-grade
inflammation, especially among women with the classic
phenotype of PCOS [1, 2]. About 44–70% of patients with
PCOS have been found to be insulin resistant [3, 4]. Insulin
resistance and increased inflammatory markers such as C-
reactive protein (CRP) levels in women with PCOS are
associated with an elevated risk of developing metabolic
syndrome (MetS), type 2 diabetes mellitus (T2DM), and
cardiovascular disease [5–7].
Probiotics are suggested to improve insulin resistance
and CRP among patients with metabolic syndrome and
related disorders [8, 9]. Findings on the effects of
probiotics on glycemic control and CRP levels among
women with PCOS are controversial. In a study by
Samimi et al. [10], synbiotic supplementation for 12 weeks
among women with PCOS significantly improved markers
of insulin metabolism; however, it did not affect fasting
glucose levels. In addition, Lactobacillus supplementation
for 12 weeks among women with PCOS significantly im-
proved inflammatory markers through increasing interleu-
kin 10 (IL-10), and reducing high sensitivity C-reactive
protein (hs-CRP), and IL-6 [11]. Conversely, 8-week pro-
biotic supplementation trials prescribed to patients with
PCOS showed no effect on parameters related to insulin
metabolism and CRP levels [12].
This study aims to systematically review the previous
randomized clinical trials (RCTs) on the effects of probi-
otic supplementation on clinical symptoms, weight loss,
glycemic control, lipid and hormonal profiles, and bio-
markers of inflammation and oxidative stress among wom-
en with PCOS and to summarize the available findings in a
meta-analysis, if possible.
Methods
Search Strategy
Eligible studies were identified through systematically
searching the Cochrane Library, Embase, Medline, and
Web of Science databases until 30th of January 2019. To
increase search sensitivity, the authors manually reviewed
the reference list of the relevant studies. Articles studying
the association between probiotic supplementation and
clinical symptoms, weight loss, glycemic control, lipid
and hormonal profiles, and biomarkers of inflammation
and oxidative stress were retrieved by including the
fol lowing search terms and text words: pat ients
(BPCOS^), intervention (Bprobiotic,^ OR Bsynbiotic,^
OR Bsymbiotic,^ AND Bsupplementation,^ OR Bintake^),
and outcomes (Bweight^ OR Bbody max index (BMI)^ OR
Bweight loss^ OR Bfasting plasma glucose (FPG)^ OR
BInsulin^ OR Bhomeostatic model assessment for insulin
resistance (HOMA-IR)^ OR Bquantitative insulin sensi-
tivity check index (QUICKI)^ OR Bglycemic control^
OR Btriglycerides^ OR Bvery-low-density lipoprotein-
cholesterol (VLDL-cholesterol)^ OR Btotal cholesterol^
OR Blow-dens i ty l ipopro te in-choles te ro l (LDL-
cholesterol)^ OR Bhigh-density lipoprotein-cholesterol
(HDL-cholesterol)^ OR Blipid profiles^ OR BC-reactive
protein (CRP)^ OR Bnitric oxide (NO)^ OR Btotal antiox-
idant capacity (TAC)^ OR Bglutathione (GSH)^ OR B
malondialdehyde (MDA)^ OR Binflammation markers^
OR Boxidative stress markers^ OR Bmodified ferriman-
gallwey (mF-G) or hirsutism^ OR Btotal testosterone^
OR Bdehydroepiandrosterone sulfate levels (DHEAS)^
OR Bsex hormone binding globulin (SHBG)^ OR
Bhormonal profiles^). The strategy searches were individ-
ually performed by two researchers. The search strategy
was restricted to RCTs published in English. After papers
were screened by their titles and/or abstracts, the full text
versions of related RCTs were retrieved for further
assessment.
Articles screened by title and 
abstract (n=194)
Full text articles assessed for the 
eligibility (n=27)
Studies included in this study 
(n=11)
1. Probiotic supplementation (n=7)
2. Synbiotic supplementation (n=4)
Article excluded (n=238) due to duplicate,
not randomized controlled trials, review and 
not human study
Excluded; non-relevant articles (n=167)
Articles excluded (n=16):
1. Participants were not diagnosed with 
polycystic ovary syndrome (n=14)
2. No use of synbiotic/probiotic (n=1)
3. Animal study (n=1)
Articles identified through 
electronic database search (n=432)
Fig. 1 Literature search and review flowchart for selection of studies
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Inclusion and Exclusion Criteria
We included studies that reported using human subjects with
RCTs, included women with PCOS, and administrated probi-
otic and/or synbiotic supplementation as interventions. RCTs
that did not report mean (SD) changes of clinical symptoms,
weight loss, glycemic control, lipid and hormonal profiles,
and biomarkers of inflammation and oxidative stress for the
intervention and placebo groups, abstracts without full article,
case reports, and RCTs that did not catch at least required
score of quality assessment process were excluded.
Quality Assessment
Two independent investigators (VO and MA) have
assessed the quality of included studies and extracted data
using the Cochrane Collaboration Risk of Bias tool and the
standard forms of Microsoft Excel 2007, respectively. The
Cochrane Collaboration Risk of Bias tool includes the fol-
lowing criteria: randomization generation, allocation con-
cealment, blinding of subjects and outcome assessment,
incomplete outcome data, selective outcome reporting,
and other sources of bias. The following data of eligible
Table 1 Characteristics of included studies
Authors (ref) Publication
years
Control/
intervention
(sample size)
Age (control
vs.
intervention)
Duration
(week)
Intervention
Samimi et al. [10] 2018 30/30 27.3 ± 6.1,
27.0 ± 5.6
12 weeks Synbiotic capsule contained Lactobacillus acidophilus, Lactobacillus
casei, and Bifidobacterium bifidum (2 × 109 CFU/g each) plus
800 mg inulin
Karimi et al. [13] 2018 49/50 29 ± 5.1,
28.1 ± 5.5
12 weeks Synbiotic capsule (500 mg) contained Lactobacillus acidophilus
3 × 1010 CFU/g, Lactobacillus casei 3 × 109 CFU/g, Lactobacillus
bulgaricus 5 × 108 CFU/g, Lactobacillus rhamnosus
7 × 109 CFU/g, Bifidobacterium longum 1 × 109 CFU/g,
Bifidobacterium breve 2 × 1010 CFU/g and Streptococcus
thermophilus 3 × 108 CFU/g + prebiotic inulin
(fructo-oligosaccharide)
Ahmadi et al. [14] 2017 30/30 24.8 ± 5.1,
25.2 ± 5.4
12 weeks Probiotic capsule contained Lactobacillus acidophilus, Lactobacillus
casei and Bifidobacterium bifidum (2 × 109 CFU/g each)
Shoaei et al. [12] 2015 33/32 25.72 ± 0.1,
26.5 ± 0.1
8 weeks Probiotic capsule (500 mg) contained Lactobacillus casei
7 × 109 CFU/g, Lactobacillus acidophilus 2 × 109 CFU/g,
Lactobacillus rhamnosus 1.5 × 109 CFU/g, Lactobacillus
bulgaricus 2 × 108 CFU/g, Bifidobacterium breve 2 × 1010 CFU/g,
Bifidobacterium longum 7 × 109 CFU/g, Streptococcus
thermophiles 1.5 × 109 CFU/g
Karamali et al.
[15]
2018 30/30 27.7 ± 4.7,
27.2 ± 4.6
12 weeks Probiotic capsule contained Lactobacillus acidophilus, Lactobacillus
casei and Bifidobacterium bifidum (2 × 109 CFU/g each)
Ghanei et al. [11] 2018 30/30 28.96 ± 0.98,
30.06 ± 1.-
06
12 weeks Probiotic capsule (1000 mg) contained Lactobacillus acidophilus,
Lactobacillus plantarum, Lactobacillus fermentum, and
Lactobacillus Gasseri (1 × 109 CFU of each)
Nasri et al. [16] 2018 30/30 25.9 ± 5.2,
25.7 ± 5.5
12 weeks Synbiotic capsule contained Lactobacillus acidophilus, Lactobacillus
casei, and Bifidobacterium bifidum (2 × 109 CFU/g each) plus
800 mg inulin
Shabani et al. [17] 2018 30/30 26.8 ± 5.1,
27.7 ± 6.9
12 weeks Probiotic capsule contained Lactobacillus acidophilus, Lactobacillus
reuteri, Lactobacillus fermentum, and Bifidobacterium bifidum
(2 × 109 CFU/g each) + 200 mcg selenium
Jamilian et al. [18] 2018 30/30 25.6 ± 3.8,
26.0 ± 5.3
12 weeks Probiotic capsule contained Lactobacillus acidophilus, Lactobacillus
reuteri, Lactobacillus fermentum, and Bifidobacterium bifidum
(2 × 109 CFU/g each) + 200 mcg selenium
Esmaeilinezhad (a)
et al. [19]
2018 22/22 29.30 ± 7.46,
30.04 ± 6.-
39
8 weeks Synbiotic pomegranate juice 2 lit per week contained Lactobacillus
(4 × 108 CFU/g) plus 40 g inulin
Esmaeilinezhad
(b) et al. [19]
2018 21/21 30.60 ± 7.43,
29.52 ± 5.-
82
8 weeks Synbiotic beverage 2 lit per week contained Lactobacillus
(4 × 108 CFU/g) plus 40 g inulin
Ostadmohammadi
et al. [20]
2019 30/30 25.4 ± 5.1,
24.4 ± 4.7
12 weeks Probiotic capsule contained Lactobacillus acidophilus, Lactobacillus
reuteri, Lactobacillus fermentum, and Bifidobacterium bifidum
(2 × 109 CFU/g each) + 50,000 IU vitamin D every 2 weeks
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RCTs were extracted: first authors’ name, year of publica-
tion, mean age of participants, mean (SD) changes of glu-
cose metabolism (including weight, BMI, FPG, insulin,
HOMA-IR, QUICKI, triglycerides, VLDL-, total-, LDL-,
and HDL-cholesterol, CRP, NO, TAC, GSH, MDA, mF-G
or hirsutism, total testosterone, DHEAS, SHBG, total sam-
ple size, number of participants in the intervention and
control groups, study design, type of intervention, and du-
ration of intervention. When there were disagreements
among the investigators, a third author (ZA) would resolve
the dispute through a guided discussion.
Statistical Methods
All statistical analyses of the present study were conducted
by using STATA version 12.0 (Stata Corp., College
Station, TX) and RevMan software (Cochrane Review
Manager, version 5.2). Heterogeneity between studies
Table 2 Estimation of the standardized differencemeans of weight loss, glycemic control, lipid and hormonal profiles, and biomarkers of inflammation
and oxidative stress with CI 95% between the intervention and control groups
Variable Number of
study
Standardized mean
difference
CI 95% P value Heterogeneity
I2
(%)
Q P value
Weight Change intervention vs. placebo
group
9 − 0.30 − 0.53,
− 0.07
0.01 42.5 13.91 0.08
BMI Change intervention vs. placebo
group
9 − 0.29 − 0.54,
− 0.03
0.02 50.7 16.23 0.03
FPG Change intervention vs. placebo
group
7 − 0.26 − 0.45,
− 0.07
< 0.01 0.0 2.35 0.88
Insulin Change intervention vs. placebo
group
7 − 0.52 − 0.81,
− 0.24
< 0.001 52.2 12.55 0.05
HOMA-IR Change intervention vs. placebo
group
7 − 0.53 − 0.79,
− 0.26
< 0.001 44.5 10.82 0.09
QUICKI Change intervention vs. placebo
group
7 0.41 0.11, 0.70 < 0.01 55.5 13.47 0.03
Triglycerides Change intervention vs. placebo
group
3 − 0.69 − 0.99,
− 0.39
< 0.001 0.0 0.28 0.86
VLDL-cholesterol Change intervention vs. placebo
group
3 − 0.69 − 0.99,
− 0.39
< 0.001 0.0 0.27 0.87
Total cholesterol Change intervention vs. placebo
group
3 − 0.26 − 0.67, 0.15 0.22 48.4 3.88 0.14
LDL-cholesterol Change intervention vs. placebo
group
3 − 0.12 − 0.66, 0.42 0.66 70.2 6.71 0.03
HDL-cholesterol Change intervention vs. placebo
group
3 0.04 − 0.25, 0.33 0.79 0.0 0.44 0.81
CRP Change intervention vs. placebo
group
7 − 1.26 − 2.14,
− 0.37
< 0.01 94.6 111.45 < 0.001
NO Change intervention vs. placebo
group
4 0.33 0.08, 0.59 0.01 0.0 2.95 0.39
TAC Change intervention vs. placebo
group
4 0.64 0.38, 0.90 < 0.001 0.0 1.95 0.58
GSH Change intervention vs. placebo
group
4 0.26 0.01, 0.52 0.04 0.0 2.00 0.57
MDA Change intervention vs. placebo
group
4 − 0.90 − 1.16,
− 0.63
< 0.001 0.0 1.72 0.63
mF-G Change intervention vs. placebo
group
4 − 0.58 − 1.01,
− 0.16
< 0.01 62.6 8.02 0.04
Total testosterone Change intervention vs. placebo
group
6 − 0.58 − 0.82,
− 0.34
< 0.001 10.4 5.58 0.34
DHEAS Change intervention vs. placebo
group
2 0.06 − 0.77, 0.89 0.88 80.8 5.21 0.02
SHBG Change intervention vs. placebo
group
4 0.46 0.08, 0.85 0.01 55.7 6.77 0.08
BMI, body max index; FPG, fasting plasma glucose; HOMA-IR, homeostatic model assessment for insulin resistance; QUICKI, quantitative insulin
sensitivity check index; VLDL-cholesterol, very-low-density lipoprotein-cholesterol; LDL-cholesterol, low-density lipoprotein; HDL-cholesterol, high-
density lipoprotein; CRP, C-reactive protein; NO, nitric oxide; TAC, total antioxidant capacity; GSH, glutathione; MDA, malondialdehyde; mF-G,
modified ferriman-gallwey; DHEAS, dehydroepiandrosterone sulfate; SHBG, sex hormone binding globulin
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was assessed by using the Cochran Q test and I-squared
statistic (I2). I2 higher than 50% with P value < 0.05 rep-
resented significant heterogeneity. Because of the different
indications between included RCTs were used random-
effects models to perform our meta-analyses. To estimate
the standardized mean difference (SMD) and 95% confi-
dence intervals (CIs), the inverse variance method and
Cohen statistics were applied. The Egger’s regression
method was conducted on the included studies to detect
potential publication bias. Additional subgroup analyses
(such as type and duration of interventions) and sensitivity
analyses were performed to examine the source of hetero-
geneity and the contribution of one by one RCTs, respec-
tively. P values < 0.05 were considered as statistically
significant.
Results
Search Results and Trial Flow
The step by step method applied for the article screening and
selection process is outlined in Fig. 1. Through the screening
and selection process, 11 studies with 12 effect sizes of 432
citations were obtained to be suitable for the meta-analysis.
Table 1 outlines the characteristics of the included primary
RCTs. All included studies were randomized, double-blind,
and placebo-controlled trials. Nine studies investigated the
effect of probiotic supplementation on weight, nine studies
on BMI, four studies on FPG, four studies on insulin, seven
studies onHOMA-IR, seven studies onQUICKI, three studies
on triglycerides, three studies on VLDL-cholesterol, three
studies on total cholesterol, three studies on LDL-cholesterol,
three studies on HDL-cholesterol, seven studies on CRP, four
studies on NO, four studies on TAC, four studies on GSH,
four studies on MDA, four studies on mF-G, six studies on
total testosterone, two studies on DHEAS, and four studies on
SHBG levels. The intervention duration among selected pri-
mary studies were varied between 8 and 12 weeks (Table 2).
The studies’ sample sizes were ranged between 42 and 99
women. The authors’ judgements about quality of each trial
and risk of bias for included primary studies are summarized
in Fig. 2.
Pooled Effects of Probiotic on Clinical Symptom,
Weight Loss, and Metabolic Profiles
The forest plots for the effects of probiotic supplementation on
glucose metabolism are presented in Fig. 3. The findings
showed that probiotic supplementation significantly de-
creased weight (SMD − 0.30; 95% CI, − 0.53, − 0.07; P =
0.01), BMI (SMD − 0.29; 95% CI, − 0.54, − 0.03; P = 0.02),
FPG (SMD − 0.26; 95%CI, − 0.45, − 0.07; P < 0.001), insulin
(SMD − 0.52; 95% CI, − 0.81, − 0.24; P < 0.001), HOMA-IR
(SMD − 0.53; 95% CI, − 0.79, − 0.26; P < 0.001), triglycer-
ides (SMD − 0.69; 95% CI, − 0.99, − 0.39; P < 0.001),
VLDL-cholesterol (SMD − 0.69; 95% CI, − 0.99, − 0.39;
P < 0.001), CRP (SMD − 1.26; 95% CI, − 2.14, − 0.37;
P < 0.001), MDA (SMD − 0.90; 95% CI, − 1.16, − 0.63;
P < 0.001), mF-G (SMD − 0.58; 95% CI, − 1.01, − 0.16;
P < 0.01), and total testosterone levels (SMD − 0.58; 95%
CI, − 0.82, − 0.34; P < 0.001), and also increased QUICKI
Fig. 2 The methodological quality of included studies
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(SMD 0.41; 95% CI, 0.11, 0.70; P < 0.001), NO (SMD 0.33;
95% CI, 0.08, 0.59; P = 0.01), TAC (SMD 0.64; 95% CI,
0.38, 0.90; P < 0.001), GSH (SMD 0.26; 95% CI, 0.01,
0.52; P = 0.04), and SHBG levels (SMD 0.46; 95% CI, 0.08,
0.85; P = 0.01).
Probiotic supplementation had no significant effect on
total cholesterol (SMD − 0.26; 95% CI, − 0.67, 0.15; P =
0.22), LDL-cholesterol (SMD − 0.12; 95% CI, − 0.66,
0.42; P = 0.66), HDL-cholesterol (SMD 0.04; 95% CI, −
0.25, 0.33; P = 0.79), and DHEAS levels (SMD 0.06; 95%
CI, − 0.77, 0.89; P = 0.88).
Subgroup and Sensitivity Analysis
According to existence heterogeneity, subgroup analyses
were conducted based on potential suspected variables in-
cluding, type of interventions (synbiotic vs. probiotic
Weight 
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Fig. 3 Meta-analysis clinical symptom, weight loss and metabolic profiles in probiotic and placebo groups (CI = 95%)
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capsule) and duration of the intervention (< 12 weeks vs. ≥
12 weeks) (Table 3).
Sensitivity analyses were conducted and the results
remained consistent with the pooled effect for the effect
of probiotic supplementation on weight, FPG, insulin,
HOMA-IR, QUICKI, triglycerides, VLDL-cholesterol,
LDL-cholesterol, HDL-cholesterol, CRP, TAC, MDA,
mf-G, total testosterone, and DHEAS levels. In sensitivity
analysis, we found significant difference between the pre-
and post-sensitivity analysis for BMI after omitting
Shabani et al. [17] study (SMD − 0.19; 95% CI, − 0.41,
0.01), total cholesterol after omitting Ahmadi et al. [14]
study (SMD − 0.43; 95% CI, − 0.80, − 0.06), for NO after
omitting Nasri et al. [16] study (SMD 0.21; 95% CI, −
0.08, 0.50), for GSH after omitting Karamali et al. [15]
study (SMD 0.19; 95% CI, − 0.10, 0.48), and for SHBG
after omitting Karamali et al. [15] study (SMD 0.29; 95%
CI, − 0.00, 0.58).
The lower and higher pooled SMDs in the sensitivity
analyses for glucose metabolisms and CRP levels are sum-
marized in Table 4.
Publication Bias
Results of Egger’s test showed no evidence of significant pub-
lication bias for weight (B = − 4.40,P = 0.54), BMI (B = − 4.53,
riglycerides
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.869)
Shabani A (2018)
Ahmadi S (2017)
Samimi M (2018)
ID
-0.69 (-0.99, -0.39)
-0.67 (-1.19, -0.15)
-0.60 (-1.12, -0.08)
-0.80 (-1.32, -0.27)
SMD (95% CI)
100.00
33.46
33.83
32.71
Weight
0-1.32 1.32
VLDL-cholesterol
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.874)
Samimi M (2018)
ID
Shabani A (2018)
Ahmadi S (2017)
-0.69 (-0.99, -0.39)
-0.80 (-1.32, -0.27)
SMD (95% CI)
-0.67 (-1.19, -0.15)
-0.61 (-1.12, -0.09)
100.00
32.71
Weight
33.48
33.80
0-1.32 1.32
Total cholesterol
NOTE: Weights are from random effects analysis
Overall  (I-squared = 48.4%, p = 0.144)
ID
Samimi M (2018)
Ahmadi S (2017)
Shabani A (2018)
-0.26 (-0.67, 0.15)
SMD (95% CI)
-0.25 (-0.76, 0.26)
0.10 (-0.41, 0.61)
-0.63 (-1.15, -0.11)
100.00
Weight
33.53
33.65
32.82
0-1.15 1.15
LDL-cholesterol
NOTE: Weights are from random effects analysis
Overall  (I-squared = 70.2%, p = 0.035)
Ahmadi S (2017)
ID
Samimi M (2018)
Shabani A (2018)
-0.12 (-0.66, 0.42)
0.33 (-0.18, 0.84)
SMD (95% CI)
-0.07 (-0.57, 0.44)
-0.63 (-1.15, -0.11)
100.00
33.41
Weight
33.54
33.05
0-1.15 1.15
HDL-cholesterol
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.802)
ID
Shabani A (2018)
Ahmadi S (2017)
Samimi M (2018)
0.04 (-0.25, 0.33)
SMD (95% CI)
0.18 (-0.33, 0.68)
-0.01 (-0.52, 0.50)
-0.05 (-0.56, 0.45)
100.00
Weight
33.25
33.38
33.37
0-.684 .684
NOTE: Weights are from random effects analysis
Overall  (I-squared = 94.6%, p = 0.000)
Ghanei N (2018)
Nasri K (2018)
Karamali M (2018)
ID
Karimi E (2018)
Shoaei T (2015)
Jamilian M (2018)
Ostadmohammadi V (2019)
-1.26 (-2.14, -0.37)
-8.46 (-10.08, -6.84)
-0.54 (-1.06, -0.03)
-0.99 (-1.53, -0.46)
SMD (95% CI)
-0.50 (-0.90, -0.10)
0.48 (-0.01, 0.97)
-0.39 (-0.90, 0.12)
-0.64 (-1.16, -0.12)
100.00
10.28
14.90
14.84
Weight
15.21
14.97
14.92
14.89
0-10.1 10.1
CRP
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P = 0.57), FPG (Β = − 1.43, P = 0.46), QUIKI (Β = 6.17, P =
0.11), total cholesterol (B = − 98.89, P = 0.24), LDL-
cholesterol (Β = − 110.72, P = 0.44), HDL-cholesterol (Β =
407.54, P = 0.15), and GSH (B = 130.86, P = 0.06). There
was evidence of publication bias on insulin (B = − 6.96, P =
0.04), HOMA-IR (Β = − 6.58, P = 0.03), triglycerides (B = −
43.88, P = 0.02), VLDL (B = − 43.71, P = 0.01), CRP (Β = −
12.49, P = 0.01), NO (B = 68.06, P = 0.01), TAC (B = 49.11,
P < 0.001), MDA (B = − 34.92, P < 0.001), mF-G (B = −
44.38, P = 0.02), total testosterone (B = − 8.52, P = 0.02), and
SHBG (B = 53.80, P = 0.01). The authors applied the non-
parametric method (Duval and Tweedie) to estimate the results
of censored trials. Findings showed that summary affected the
size on profiles that had evidences of publication bias. No sig-
nificant changes were noted between the pre- and post-
intervention after including censored studies.
Discussion
To the authors’ knowledge, this paper is the first meta-
analysis of RCTs that has evaluated the effect of probiotic
NO
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.399)
ID
Ostadmohammadi V (2019)
Nasri K (2018)
Karamali M (2018)
Jamilian M (2018)
0.33 (0.08, 0.59)
SMD (95% CI)
0.11 (-0.40, 0.61)
0.71 (0.19, 1.24)
0.28 (-0.23, 0.79)
0.26 (-0.25, 0.76)
100.00
Weight
25.48
23.94
25.27
25.31
0-1.24 1.24
TAC
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.583)
Karamali M (2018)
Nasri K (2018)
Ostadmohammadi V (2019)
Jamilian M (2018)
ID
0.64 (0.38, 0.90)
0.55 (0.04, 1.07)
0.39 (-0.12, 0.90)
0.80 (0.27, 1.32)
0.84 (0.32, 1.37)
SMD (95% CI)
100.00
25.44
25.93
24.43
24.21
Weight
0-1.37 1.37
GSH
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.573)
Jamilian M (2018)
Karamali M (2018)
Nasri K (2018)
Ostadmohammadi V (2019)
ID
0.26 (0.01, 0.52)
0.27 (-0.24, 0.77)
0.47 (-0.04, 0.98)
-0.03 (-0.54, 0.48)
0.34 (-0.17, 0.85)
SMD (95% CI)
100.00
25.10
24.62
25.33
24.95
Weight
0-.983 .983
MDA
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.633)
Ostadmohammadi V (2019)
Karamali M (2018)
ID
Jamilian M (2018)
Nasri K (2018)
-0.90 (-1.16, -0.63)
-0.75 (-1.27, -0.23)
-1.09 (-1.63, -0.54)
SMD (95% CI)
-1.08 (-1.62, -0.54)
-0.71 (-1.23, -0.18)
100.00
25.83
24.04
Weight
24.09
26.04
0-1.63 1.63
mF-G
NOTE: Weights are from random effects analysis
Overall  (I-squared = 62.6%, p = 0.046)
Jamilian M (2018)
ID
Ostadmohammadi V (2019)
Nasri K (2018)
Karamali M (2018)
-0.58 (-1.01, -0.16)
-0.15 (-0.66, 0.36)
SMD (95% CI)
-0.38 (-0.89, 0.13)
-0.67 (-1.19, -0.15)
-1.18 (-1.73, -0.63)
100.00
25.54
Weight
25.40
25.05
24.02
0-1.73 1.73
Total testosterone
NOTE: Weights are from random effects analysis
Overall  (I-squared = 10.4%, p = 0.349)
Esmaeilinezhad Z (a) (2018)
Esmaeilinezhad Z (b) (2018)
Karamali M (2018)
Nasri K (2018)
Jamilian M (2018)
Ostadmohammadi V (2019)
ID
-0.58 (-0.82, -0.34)
-0.61 (-1.21, -0.00)
-1.27 (-1.93, -0.60)
-0.61 (-1.13, -0.10)
-0.41 (-0.92, 0.10)
-0.53 (-1.05, -0.02)
-0.32 (-0.83, 0.19)
SMD (95% CI)
100.00
13.86
11.64
18.33
18.75
18.52
18.90
Weight
0-1.93 1.93
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supplementation on glucose metabolism and CRP levels
among patients with PCOS. The findings showed that pro-
biotic supplementation may result in an improvement in
weight, BMI, FPG, insulin, HOMA-IR, triglycerides,
VLDL-cholesterol, CRP, MDA, hirsutism, total testoster-
one, QUICKI, NO, TAC, GSH, and SHBG but did not
affect dehydroepiandrosterone sulfate levels, and total-,
LDL-, and HDL-cholesterol levels in patients with PCOS.
The hypothesis that probiotics may be involved in main-
tenance of healthy gut microbiota, management of glyce-
mic control, and can modulate inflammatory marker has
received much attention recently. Two previous meta-
analyses among patients with diabetes concluded that
probiotics supplementation significantly decreased insulin
resistance and HbA1c levels [21, 22]. In addition, a recent
meta-analysis, with 11 RCTs and 614 subjects, demonstrat-
ed similar results [23]. They observed that probiotic ad-
ministration to people with diabetes significantly de-
creased FPG, HbA1c, insulin, and HOMA-IR. In another
meta-analysis of 12 RCTs with a total population of 684
patients with diabetes, probiotic administration was asso-
ciated with significant reductions in both HbA1c and insu-
lin levels [24]. Insulin resistance plays an important role in
approximately 70–80% of obese women and in 15–30% of
lean women diagnosed with PCOS [1], and represents the
pathogenic association between metabolic and reproduc-
tive status in PCOS. Moreover, the decrease in insulin sen-
sitivity has been attributed to post-receptor changes in in-
tracellular signaling pathways of insulin occurring in wom-
en with PCOS [25]. It must be kept in mind that in the
current meta-analysis study, insulin and QUICKI remained
unchanged and is opposing to the current study’s hypoth-
esis. This may have occurred for a few different reasons.
The shorter duration of the intervention might be one pos-
sible explanation for the observed discrepancy. Most of the
included RCTs were performed between 8 and 12 weeks,
which is far shorter than those observational studies con-
ducted with patients diagnosed with other metabolic dis-
eases. Longer duration of RCTs is required to obtain a
more reliable conclusion. Additionally, the absence of sig-
nificant effect on insulin and QUICKI in Asians partici-
pants may have attributed to the included PCOS subjects
in RCTs. The subjects recruited in the observational studies
had different baseline insulin levels and QUICKI. Thus, it
was assumed that early intervention with probiotic supple-
mentation among women with PCOS may be important as
the beneficiary effect of probiotic on insulin and QUICKI
may increase, when individuals have longer supplementa-
tion duration and similar baseline levels of insulin and
QUICKI. Probiotics may improve the glycemic control
through modulating reducing inflammatory cytokines
[26] and upregulation in the expression of peroxisome
proliferator-activated receptor gamma gene [27, 28].
We found that probiotic supplementation among pa-
tients with PCOS did not affect CRP levels. CRP is an
important inflammatory factor for patients with diabetes
and other metabolic disorders progression and complica-
tions [29]. A previous meta-analysis also reported non-
significant effects of probiotics on CRP concentrations
in people with T2DM [24]. In a meta-analysis conducted
among people with T2DM, no significant effects were
observed by probiotics supplementation on CRP [21]. In
another meta-analysis, probiotic supplementation was giv-
en to colorectal cancer patients and CRP levels signifi-
cantly decreased CRP [30]. Overall, in addition to those
findings above, different study designs, sample size, dif-
ferent dosages of probiotic and/or synbiotic used, the use
of various probiotic preparations and differences in strain-
specific efficacy [31–33] along with characteristics of
study participants might explain the discrepancies among
the different studies. These results suggested that although
probiotics have an important function in intestinal immu-
nological modulation [34], the evidence for an effect on
CRP concentrations in patients with PCOS is scarce.
Alteration in microbial composition and diversity of the
human gastrointestinal tract is considered essential for
improvement in metabolic disorders, oxidative stress, in-
flammation, and proliferation [35]. The intestinal
DHEAS
NOTE: Weights are from random effects analysis
Overall  (I-squared = 80.8%, p = 0.022)
Karamali M (2018)
Nasri K (2018)
ID
0.06 (-0.77, 0.89)
0.48 (-0.03, 0.99)
-0.36 (-0.87, 0.15)
SMD (95% CI)
100.00
49.94
50.06
Weight
0-.994 .994
SHBG
NOTE: Weights are from random effects analysis
Overall  (I-squared = 55.7%, p = 0.080)
Jamilian M (2018)
ID
Karamali M (2018)
Nasri K (2018)
Ostadmohammadi V (2019)
0.46 (0.08, 0.85)
0.12 (-0.39, 0.62)
SMD (95% CI)
1.00 (0.46, 1.53)
0.57 (0.06, 1.09)
0.20 (-0.31, 0.71)
100.00
25.45
Weight
24.13
25.01
25.41
0-1.53 1.53
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microbiota can be modulated by several factors including,
surgery, aging, environmental exposures, radiation, medi-
cines, lifestyle, diet, and host genetic background [36].
Another important way of modulating the intestinal mi-
crobiota is probiotics supplementation. Modifications to
the microbial community can prevent or treat various gas-
trointestinal disorders such as irritable bowel syndrome
and inflammatory bowel disease [37], as well as systemic
diseases such as eczema [38], respiratory infections [39],
asthma [40], and diabetes [23]. Probiotics intake may
change gut dysbiosis by the several effects such as reduc-
ing microbial genotoxicity, altering the metabolites pro-
duced by the microbiota, competing with the pathogenic
bacteria, increasing the intestinal barrier, and increasing
the innate immune response [41, 42]. Therefore, microbi-
ota changed following probiotic supplementation can pro-
mote the intestinal homeostasis and regulate metabolic
disorders, as well as inflammatory responses.
The current meta-analysis had a few limitations. There
were few eligible RCTs and most of them had a modest
Table 3 The effects of probiotic supplementation on weight loss, glycemic control, lipid and hormonal profiles, and biomarkers of inflammation and
oxidative stress with CI 95% between based on subgroup analysis
Variable Number of SMD
included
Subgroups Pooled effect
estimate
95% CI I2
(%)
Overall I2
(%)
BMI Type of intervention 4 Synbiotic
capsule
− 0.03 − 0.30, 0.25 0.0 50.7
5 Probiotic
capsule
− 0.47 − 0.79,
− 0.14
48.6
Duration of study
(week)
7 ≥ 12 weeks − 0.29 − 0.61, 0.02 62.5
2 < 12 weeks − 0.26 − 0.68, 0.17 0.0
Insulin Type of intervention 4 Synbiotic
capsule
− 0.50 − 0.93,
− 0.06
63.5 52.2
3 Probiotic
capsule
− 0.57 − 0.98,
− 0.16
47.5
Duration of study
(week)
4 ≥ 12 weeks − 0.58 − 1.03,
− 0.13
70.5
3 < 12 weeks − 0.44 − 0.78,
− 0.09
11.5
QUICKI Type of intervention 4 Synbiotic
capsule
0.44 − 0.05, 0.92 70.2 55.5
3 Probiotic
capsule
0.38 0.01, 0.77 41.3
Duration of study
(week)
4 ≥ 12 weeks 0.48 0.06, 0.90 66.1
3 < 12 weeks 0.30 − 0.17, 0.77 51.2
LDL-cholesterol Type of intervention 1 Synbiotic
capsule
− 0.07 − 0.57, 0.44 – 70.2
2 Probiotic
capsule
− 0.15 − 1.09, 0.79 85.0
Duration of study
(week)
3 ≥ 12 weeks − 0.12 − 0.66, 0.42 70.2
– < 12 weeks – – –
CRP Type of intervention 2 Synbiotic
capsule
− 0.52 − 0.83,
− 0.20
0.0 94.6
5 Probiotic
capsule
− 1.73 − 3.13,
− 0.33
96.4
Duration of study
(week)
6 ≥ 12 weeks − 1.57 − 2.54,
− 0.60
94.6
1 < 12 weeks 0.48 − 0.01, 0.97 –
mF-G Type of intervention 1 Synbiotic
capsule
− 0.67 − 1.19,
− 0.15
– 62.6
3 Probiotic
capsule
− 0.56 − 1.16, 0.04 74.5
Duration of study
(week)
4 ≥ 12 weeks − 0.58 − 1.01,
− 0.16
62.6
– < 12 weeks – – –
BMI, body max index; QUICKI, quantitative insulin sensitivity check index; LDL-cholesterol, low-density lipoprotein; CRP, C-reactive protein; mF-G,
modified ferriman-gallwey
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Table 4 The assess of contribution one by one trials in association between probiotic supplementation and weight loss, glycemic control, lipid and
hormonal profiles, and biomarkers of inflammation and oxidative stress using sensitivity analysis
Variable Pre-sensitivity analysis Upper and lower of
effect size
Post-sensitivity analysis
No. of studies
included
Pooled SMD
(random effect)
95% CI Pooled SMD
(random effect)
95% CI Excluded studies
Weight 9 − 0.30 − 0.53,
− 0.07
Upper − 0.21 − 0.40,
− 0.02
Shabani
Lower − 0.34 − 0.53,
− 0.16
Nasri
BMI 9 − 0.29 − 0.54,
− 0.03
Upper − 0.19 − 0.41,
0.01
Shabani
Lower − 0.35 − 0.59,
− 0.12
Nasri
FPG 7 − 0.26 − 0.45,
− 0.07
Upper − 0.21 − 0.41,
− 0.01
Ahmadi
Lower − 0.30 − 0.52,
− 0.08
Karimi
Insulin 7 − 0.52 − 0.81,
− 0.24
Upper − 0.45 − 0.75,
− 0.16
Shabani
Lower − 0.62 − 0.85,
− 0.39
Karimi
HOMA-IR 7 − 0.53 − 0.79,
− 0.26
Upper − 0.47 − 0.74,
− 0.19
Samimi
Lower − 0.62 − 0.84,
− 0.40
Karimi
QUICKI 7 0.41 0.11, 0.70 Upper 0.49 0.20, 0.78 Karimi
Lower 0.32 0.03, 0.60 Samimi
Triglycerides 3 − 0.69 − 0.99,
− 0.39
Upper − 0.63 − 1.00,
− 0.26
Samimi
Lower − 0.73 − 1.10,
− 0.36
Ahmadi
VLDL-cholesterol 3 − 0.69 − 0.99,
− 0.39
Upper − 0.63 − 1.00,
− 0.26
Samimi
Lower − 0.73 − 1.10,
− 0.36
Ahmadi
Total cholesterol 3 − 0.26 − 0.67,
0.15
Upper − 0.07 − 0.43,
0.28
Shabani
Lower − 0.43 − 0.80,
− 0.06
Ahmadi
LDL-cholesterol 3 − 0.12 − 0.66,
0.42
Upper 0.12 − 0.25,
0.51
Shabani
Lower − 0.34 − 0.89,
0.20
Ahmadi
HDL-cholesterol 3 0.04 − 0.25,
0.33
Upper 0.08 − 0.27,
0.44
Samimi
Lower − 0.03 − 0.38,
0.32
Shabani
CRP 7 − 1.26 − 2.14,
− 0.37
Upper − 0.42 − 0.81,
− 0.04
Ghanei
Lower − 1.56 − 2.53,
− 0.59
Shoaei
NO 4 0.33 0.08, 0.59 Upper 0.41 0.11, 0.70 Ostadmohammadi
Lower 0.21 − 0.08,
0.50
Nasri
TAC 4 0.64 0.38, 0.90 Upper 0.72 0.42, 1.03 Nasri
Lower 0.57 0.27, 0.87 Jamilian
GSH 4 0.26 0.01, 0.52 Upper 0.35 0.06, 0.65 Nasri
Lower 0.19 − 0.10,
0.48
Karamali
MDA 4 − 0.90 − 1.16,
− 0.63
Upper − 0.83 − 1.14,
− 0.53
Karamali
Probiotics & Antimicro. Prot.
number of participants. The dose response association
between supplementation dose, glycemic control, and in-
flammatory markers was unable to be evaluated due to
the low number of studies included. The number of stud-
ies evaluating lipid profiles and inflammatory cytokines
in women with PCOS were low. Therefore, we did not
analyze these variables in the current meta-analysis.
Inflammatory cytokines are signals in the intestinal im-
mune system, contributing to the understanding of gut
inflammation status, which would affect the overall con-
dition of inflammation among women with PCOS. It
would be interested to assess gut microbiome changes
by probiotic treatment. Unfortunately, we were unable
to examine the gut microbiome changes following probi-
otic supplementation as a treatment option, because none
of the studies evaluated that.
Conclusions
Probiotic supplementation may result in an improvement in
weight, BMI, FPG, insulin, HOMA-IR, triglycerides, VLDL-
cholesterol, CRP, MDA, hirsutism, total testosterone,
QUICKI, NO, TAC, GSH, and SHBG, but did not affect de-
hydroepiandrosterone sulfate levels, and total-, LDL-, and
HDL-cholesterol levels in patients with PCOS.
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